Crescent Biopharma
CBIO
43 hedge funds and large institutions have $31.7M invested in Crescent Biopharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 7 closing their positions.
4,300% more call options, than puts
Call options by funds: $132K | Put options by funds: $3K
0.05% less ownership
Funds ownership: 0.57% → 0.52% (-0.05%)
9% less funds holding
Funds holding: 47 → 43 (-4)
26% less capital invested
Capital invested by funds: $42.7M → $31.7M (-$11M)
56% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 18
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$103K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$45.8K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$21.1K |
| 4 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$11.7K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$497K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$344K |
| 3 |
Millennium Management
New York
|
-$337K |
| 4 |
Two Sigma Advisers
New York
|
-$312K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$255K |
CBIO Hedge Fund Activity: Q1 2022 in Review
43 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2022, worth a combined $31.7M — down 26% from $42.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CBIO and 3 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 8 added.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $103K. The largest seller was Vanguard Group, cutting an estimated $497K.
- 43 institutional investors held Crescent Biopharma (CBIO) as of Q1 2022, down from 47 in Q4 2021.
- Funds reported $31.7M of Crescent Biopharma stock for Q1 2022, down 26% quarter-over-quarter.
- 3 funds opened new Crescent Biopharma positions in Q1 2022 and 7 closed out, a net change of -4 holders.
- The largest Crescent Biopharma buyer in Q1 2022 was Pura Vida Investments, an estimated $103K added.
- The largest Crescent Biopharma seller in Q1 2022 was Vanguard Group, an estimated $497K sold.
Based on aggregated 13F filings for Q1 2022.